Cambium Bio
ASX:CMBLMelbourne, Australia· Est.
Australian‑based regenerative biotech advancing platelet‑lysate and MSC‑based therapies for eye, joint and wound indications.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian‑based regenerative biotech advancing platelet‑lysate and MSC‑based therapies for eye, joint and wound indications.
Dry Eye DiseaseKnee OsteoarthritisWound Healing
Technology Platform
A proprietary biologics platform that combines human platelet lysate with mesenchymal stem cells to create regenerative, anti‑inflammatory therapies.
Opportunities
Successful Phase 3 approval of Elate Ocular® could unlock a fast‑growing ocular market and fund expansion of orthopedic and wound‑healing programs.
Risk Factors
Clinical trial setbacks, regulatory hurdles, and competition from larger regenerative firms could delay or diminish commercial potential.
Competitive Landscape
Key competitors include Athersys, Mesoblast, and other MSC‑based biotech firms; Cambium differentiates through its combined platelet‑lysate platform and focus on ocular indications.